Literature DB >> 2981875

Activator protein required for the enzymatic hydrolysis of cerebroside sulfate. Deficiency in urine of patients affected with cerebroside sulfatase activator deficiency and identity with activators for the enzymatic hydrolysis of GM1 ganglioside and globotriaosylceramide.

S C Li, H Kihara, S Serizawa, Y T Li, A L Fluharty, J S Mayes, L J Shapiro.   

Abstract

Urine specimens from two sibs affected with cerebroside sulfatase activator deficiency were examined to ascertain whether the deficiency of the supplementary activator protein required for the enzymatic hydrolysis of cerebroside sulfate was also evident in urine. Material from chromatographic fractionations was examined for the activator activity to avoid ambiguities resulting from protein inhibition. There were substantial deficits in all chromatographic fractions corresponding to activator-containing fractions of control urines. Since patient urines contained elevated amounts of lactosylceramide, digalactosylceramide, and globotriaosylceramide and since similarities between activators for cerebroside sulfate and GM1 ganglioside hydrolyses had been noted previously, the chromatographic fractions were also examined for activators in other glycosphingolipid hydrolase systems. There was coincidence of activators for the GM1 ganglioside/beta-galactosidase and the globotriaosylceramide/alpha-galactosidase A reactions with the cerebroside sulfatase activator in control urine fractions, and the patients' urines were deficient in activator activities for the three reactions. Identity of the three activators was suggested and antiserum to purified GM1 ganglioside activator was used to test this possibility. There were depressed levels of cross-reacting material in fractions of patient urines by Ouchterlony double diffusion and in unfractionated urine by enzyme-linked immunosorbent assay. Purified activators for the cerebroside sulfate and GM1 ganglioside systems showed lines of identity with no spurring on Ouchterlony double diffusion, identical mobility on immunoelectrophoresis, and similar stimulatory activities toward hydrolysis of the three glycosphingolipid species by their respective enzymes. Finally, the three activator activities were retained by anti-GM1-activator IgG coupled to Sepharose 4B. The results suggest strongly that the same protein entity serves as activator for the enzymatic hydrolysis of cerebroside sulfate, GM1 ganglioside, and globotriaosylceramide.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981875

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Evidence for two cDNA clones encoding human GM2-activator protein.

Authors:  S Nagarajan; H C Chen; S C Li; Y T Li; J M Lockyer
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

2.  Late-onset Krabbe disease initially diagnosed as cerebroside sulfatase activator deficiency.

Authors:  A L Fluharty; L Neidengard; D Holtzman; H Kihara
Journal:  Metab Brain Dis       Date:  1986-09       Impact factor: 3.584

3.  Cloning, expression and map assignment of chicken prosaposin.

Authors:  N Azuma; H C Seo; O Lie; Q Fu; R M Gould; M Hiraiwa; D W Burt; I R Paton; D R Morrice; J S O'Brien; Y Kishimoto
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

Review 4.  The protective role of prosaposin and its receptors in the nervous system.

Authors:  Rebecca C Meyer; Michelle M Giddens; Brilee M Coleman; Randy A Hall
Journal:  Brain Res       Date:  2014-08-15       Impact factor: 3.252

5.  Saposin A: second cerebrosidase activator protein.

Authors:  S Morimoto; B M Martin; Y Yamamoto; K A Kretz; J S O'Brien; Y Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

6.  Distribution of saposin proteins (sphingolipid activator proteins) in lysosomal storage and other diseases.

Authors:  S Morimoto; Y Yamamoto; J S O'Brien; Y Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

7.  Sphingolipid activator protein 1 deficiency in metachromatic leucodystrophy with normal arylsulphatase A activity. A clinical, morphological, biochemical, and immunological study.

Authors:  W Schlote; K Harzer; H Christomanou; B C Paton; B Kustermann-Kuhn; B Schmid; J Seeger; U Beudt; I Schuster; U Langenbeck
Journal:  Eur J Pediatr       Date:  1991-06       Impact factor: 3.183

Review 8.  Sphingolipid activator protein deficiency in a 16-week-old atypical Gaucher disease patient and his fetal sibling: biochemical signs of combined sphingolipidoses.

Authors:  K Harzer; B C Paton; A Poulos; B Kustermann-Kuhn; W Roggendorf; T Grisar; M Popp
Journal:  Eur J Pediatr       Date:  1989-10       Impact factor: 3.183

9.  Canine GM1-gangliosidosis. A clinical, morphologic, histochemical, and biochemical comparison of two different models.

Authors:  J Alroy; U Orgad; R DeGasperi; R Richard; C D Warren; K Knowles; J G Thalhammer; S S Raghavan
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

Review 10.  Saposins and their interaction with lipids.

Authors:  A M Vaccaro; R Salvioli; M Tatti; F Ciaffoni
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.